Biography:

Dr. Liangan Chen into Department of Respiratory Medicine at Chinese PLA General Hospital, Beijing, China. One of the research work is Randomized phase II study of erlotinib as first-line or second-line therapy for EGFR mutation-positive advanced lung adenocarcinoma patients.